

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the present application.

Listing of Claims:

1. **(Currently Amended)** A method for increasing the ~~systemic exposure of cells selected from tumor cells and normal cells to~~ bioavailability of an orally administered pharmaceutically active compound, comprising:

orally administering a bioenhancer comprising an inhibitor of BCRP and said pharmaceutically active compound, wherein said inhibitor and said pharmaceutically active compound are concomitantly ~~exposed to said cells.~~ administered.

2. **(Original)** Method according to claim 1, wherein the inhibitor is administered simultaneously with the pharmaceutical compound.

3. **(Cancelled)**

4. **(Previously Presented)** Method according to claim 1, wherein the inhibitor is a selective inhibitor of BCRP.

5. **(Previously Presented)** Method according to claim 1, wherein the inhibitor is selected from acridine derivatives, quinoline derivatives, isoquinoline derivatives and combinations thereof.

6. **(Previously Presented)** Method according to claim 1, wherein the inhibitor is GF120918, XR 9051 or XR 9576.

7. **(Previously Presented)** Method according to claim 1, wherein the bioenhancer is a mycotoxin.

8. **(Original)** Method according to claim 7, wherein the mycotoxin is fumitremorgin C.

9. **(Previously Presented)** Method according to claim 1, wherein the bioenhancer has a higher affinity for BCRP than for P-gp.

10. **(Previously Presented)** Method according to claim 1, wherein the bioenhancer has a higher affinity for BCRP than for MRP.

11. **(Previously Presented)** Method according to claim 1, wherein the bioenhancer inhibits binding of ATP to a BCRP mediated and/or related drug transport protein.

12. **(Original)** Method according to claim 11, wherein the protein is BCRP.

13. **(Previously Presented)** Method according to claim 1, wherein the pharmaceutically active compound is selected from the group consisting of indolizino-quinoline derivatives, camptothecin derivatives, anthraquinone derivatives and quinazoline derivatives.

14. **(Original)** Method according to claim 13, wherein the pharmaceutically active compound is an indolizino-quinoline derivative.

15. **(Original)** Method according to claim 13, wherein the pharmaceutically active compound is a camptothecin derivative.

16. **(Original)** Method according to claim 15, wherein the pharmaceutically active compound is selected from the group consisting of topotecan, GG211, DX8951f, BNP1350, 9-aminocamptothecin, 9-nitrocamptothecin, CPT11 and any metabolites thereof.

17. **(Original)** Method according to claim 16, wherein the metabolite is SN38.

18. **(Original)** Method according to claim 13, wherein the pharmaceutically active compound is an anthraquinone derivative.

19. **(Original)** Method according to claim 18, wherein the pharmaceutically active compound is mitoxantrone.

20. **(Original)** Method according to claim 13, wherein the pharmaceutically active compound is a quinazoline derivative.

21. **(Original)** Method according to claim 20, wherein the pharmaceutically active compound is prazosin.

22. **(Currently Amended)** Pharmaceutical composition comprising a bioenhancer for increasing the bioavailability of a pharmaceutically active compound and ~~a~~ said pharmaceutically active compound, said bioenhancer comprising an inhibitor of BCRP and said pharmaceutically active compound being selected from the group consisting of indolizino-quinoline derivatives, camptothecin derivatives, anthraquinone derivatives and quinazoline derivatives.

23-29. **(Canceled)**.

30. **(Currently Amended)** A pharmaceutical composition, comprising:
an effective amount of topotecan; and
an effective ~~bioenhancing~~ amount of GF120918 to increase the bioavailability of said topotecan.

31. **(Previously Presented)** The pharmaceutical composition of claim 30, further comprising a pharmaceutically acceptable carrier suitable for oral administration.

32. **(Currently Amended)** A method for increasing the ~~systemic exposure of cells selected from tumor cells and normal cells to~~ bioavailability of orally administered camptothecin or a cytostatic camptothecin derivative, comprising:

orally administering an effective bioenhancing amount of GF120918, ~~GF120918 to said cells~~ wherein said GF120918 and said camptothecin or said cytostatic camptothecin derivative are both present at overlapping periods of time.

33. **(Previously Presented)** The method according to claim 32, wherein the GF120918 is administered simultaneously with the camptothecin or cytostatic camptothecin derivative.

34. **(Previously Presented)** The method according to claim 32, wherein said camptothecin or cytostatic camptothecin derivative is topotecan.